文献速递神经康复

解读CPASS试验:不应将运动治疗转移至亚急性期

Interpreting the CPASS Trial: Do Not Shift Motor Therapy to the Subacute Phase.
PubMed 文献 · Neurorehabil Neural Repair · 2022-12-28

CPASS试验(n=72)显示,额外20小时强化上肢治疗在卒中后2-3个月(亚急性期)开始可超过最小临床重要差异,0-1个月(急性期)有较小但统计学显著的改善,6-9个月(慢性期)未达显著改善。有观点误读为应将住院运动治疗全部转移至门诊亚急性期,但作者指出CPASS实际支持在急性期和亚急性期持续累积给予大剂量运动治疗,并强调所有参与者均接受了大量早期常规治疗(UCC),且统计限制不允许直接比较急性组与亚急性组。

要点

  • CPASS中额外20小时强化上肢治疗在亚急性期(2-3个月)改善超过MCID,慢性期未达显著。
  • 所有参与者早期接受大量常规职业治疗:前2个月平均27.9小时,第3-4个月平均9.8小时。
  • 不应将住院运动治疗转移至亚急性期,而应保留住院常规治疗并持续累积大剂量治疗。

核心结论

  • CPASS结果应解读为支持在急性期和亚急性期持续累积给予大剂量运动治疗,而非将住院治疗转移至亚急性期门诊。

研究设计与样本

  • CPASS为随机对照试验,纳入72例卒中患者,比较额外20小时强化上肢治疗与对照,按卒中后开始治疗时间分为急性组(0-1个月)、亚急性组(2-3个月)和慢性组(6-9个月)。

主要发现

  • 亚急性组(2-3个月)在Action Research Arm Test上的改善超过最小临床重要差异。
  • 急性组(0-1个月)显示较小但统计学显著的改善。
  • 慢性组(6-9个月)未显示达到统计学显著的改善。
  • CPASS参与者前2个月平均接受27.9小时常规职业治疗,第3-4个月平均接受9.8小时常规职业治疗。

关键数值与推荐

  • 额外强化上肢治疗剂量为20小时。
  • 亚急性组改善超过最小临床重要差异,急性组改善统计学显著,慢性组未达显著。
  • 常规职业治疗剂量:前2个月平均27.9小时,第3-4个月平均9.8小时。

临床怎么用

  • 不应将住院运动治疗小时数转移至亚急性期门诊,而应保留住院常规治疗。
  • 建议开展多中心剂量试验,确定住院康复后前2-3个月额外强化运动治疗能否进一步改善结局。

局限性

  • 统计限制不允许直接比较CPASS中急性组与亚急性组的结局。
  • 所有参与者均接受大量早期常规治疗,恢复效果为试验治疗与常规治疗的联合效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Critical Periods After Stroke Study (CPASS, n = 72) showed that, compared to controls, an additional 20 hours of intensive upper limb therapy led to variable gains on the Action Research Arm Test depending on when therapy was started post-stroke: the subacute group (2-3 months) improved beyond the minimal clinically important difference and the acute group (0-1 month) showed smaller but statistically significant improvement, but the chronic group (6-9 months) did not demonstrate improvement that reached significance. Some have misinterpreted CPASS results to indicate that all inpatient motor therapy should be shifted to outpatient therapy delivered 2 to 3 months post-stroke. Instead, however, CPASS argues for a large dose of motor therapy delivered continuously and cumulatively during the acute and subacute phases. When interpreting trials like CPASS, one must consider the substantial dose of early usual customary care (UCC) motor therapy that all participants received. CPASS participants averaged 27.9 hours of UCC occupational therapy (OT) during the first 2 months and 9.8 hours of UCC OT during the third and fourth months post-stroke. Any recovery experienced would therefore result not just from CPASS intensive motor therapy but the combined effects of experimental therapy plus UCC. Statistical limitations also did not allow direct comparisons of the acute and subacute group outcomes in CPASS. Instead of shifting inpatient therapy hours to the subacute phase, CPASS argues for preserving inpatient UCC. We also recommend conducting multi-site dosing trials to determine whether additional intensive motor therapy delivered in the first 2 to 3 months following inpatient rehabilitation can further improve outcomes.

来源:Neurorehabil Neural Repair,查看原文。版权归原作者所有。

引用

  1. Edwardson MA, Brady K, Giannetti ML, et al. Interpreting the CPASS Trial: Do Not Shift Motor Therapy to the Subacute Phase. Neurorehabil Neural Repair. 2022. PMID: 36575958. doi:10.1177/15459683221143461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。